Clopidogrel News and Research RSS Feed - Clopidogrel News and Research

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
Euro Heart Index 2016: France ranks 1st in heart care

Euro Heart Index 2016: France ranks 1st in heart care

Heart care in France ranks 1st among 30 measured countries, says the Euro Heart Index 2016 (EHI), published today in Brussels. The Index compares heart care in 30 European countries, with France the champion, closely followed by Norway and Sweden. [More]
New guidelines recommend use of antiplatelet therapy and exercise program for treatment of PAD

New guidelines recommend use of antiplatelet therapy and exercise program for treatment of PAD

New guidelines for the treatment of peripheral artery disease (PAD), include recommendations on the use of antiplatelet therapy to reduce the risk of blood clots and statin drugs to lower cholesterol and advise PAD patients to participate in a structured exercise program. [More]
NCDR provides data to study appropriate use of oral anticoagulant therapy

NCDR provides data to study appropriate use of oral anticoagulant therapy

The American College of Cardiology's National Cardiovascular Data Registry was the source of data for research published throughout 2016, including a study examining if atrial fibrillation patients are being prescribed oral anticoagulants, how appropriate use criteria correlates to angioplasty rates and the variation among racial groups for revascularization procedures. [More]
Study shows non-inferiority of short-term dual antiplatelet therapy in patients with DES placement

Study shows non-inferiority of short-term dual antiplatelet therapy in patients with DES placement

A short-term course of dual antiplatelet therapy (DAPT) is non-inferior to a longer course in patients who have undergone placement of a particular kind of drug-eluting stent (DES), researchers reported here. [More]
New study to examine genomics of anti-platelet therapy after coronary interventions

New study to examine genomics of anti-platelet therapy after coronary interventions

Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty. [More]
'Novel' analysis addresses antiplatelet benefits in real-world CHD patients

'Novel' analysis addresses antiplatelet benefits in real-world CHD patients

Researchers demonstrate a means of gauging the effects of drugs tested in randomised trials in real-world patients. [More]
CYP2C19 gene variants undermine clopidogrel stroke prevention

CYP2C19 gene variants undermine clopidogrel stroke prevention

The first look at CYP2C19 mutations in the context of a randomised controlled trial has confirmed suspicions that they affect the efficacy of clopidogrel in patients with acute stroke. [More]
Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Doctors worried about dangerous blood clots in patients undergoing a coronary artery procedure— such as angioplasty to treat a heart attack — will often administer antiplatelet therapy to head off complications. [More]
Younger women more likely to experience one-year adverse cardiovascular events after PCI

Younger women more likely to experience one-year adverse cardiovascular events after PCI

Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are more likely to experience one-year adverse cardiovascular events due to risk factors such as diabetes and chronic kidney disease, yet they are less likely to receive potent antiplatelet therapy than men. The PROMETHEUS study found that outcomes for both men and women post-PCI are dependent on their baseline risk factors, not their sex. [More]
UPMC uses simple gene test to personalize medications for patients undergoing heart catheterization

UPMC uses simple gene test to personalize medications for patients undergoing heart catheterization

Patients who go to UPMC Presbyterian for heart catheterization and who receive a stent to treat clogged arteries are now being screened with a simple blood test to determine if they have a gene variant that makes them less likely to respond to a blood-thinning medication commonly prescribed after the procedure. [More]
New study finds efficacy of novel intravenous blood thinner in women

New study finds efficacy of novel intravenous blood thinner in women

Percutaneous coronary intervention (PCI) is a staple of modern day medicine in which cardiologists place a stent in a blood vessel around the heart in order to restore blood flow in people with heart disease. Blood thinners allow for the procedure to be completed with a reduced risk of certain complications such as clots. [More]
XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research. [More]
Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention (PCI), according to findings from the ATLANTIC-H24 study presented for the first time today at ESC Congress. [More]
Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF). [More]
DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Fatal bleeding is rare with extended dual antiplatelet therapy, according to a secondary analysis of the DAPT Study presented for the first time today at ESC Congress. Bleeding-related mortality accounted for a minority of deaths in patients treated with dual antiplatelet therapy beyond one year. [More]
Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today. [More]
Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

For the first time, ESC Guidelines published today give the highest degree of recommendation for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS). [More]
ESC Congress to highlight results from global trials in six press conferences

ESC Congress to highlight results from global trials in six press conferences

Members of the press will be the first to hear the highly anticipated results from global trials in six press conferences devoted to hot lines research. [More]
Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

Researchers conducted a prospective observational study in elderly patients and adult patients receiving antiplatelet therapy who presented with mild head injury at two trauma hospitals in Vienna: the Trauma Hospital Meidling and the Donauspital. [More]
Substantial pharmacogenetic information available on cardiovascular drugs

Substantial pharmacogenetic information available on cardiovascular drugs

There is a wealth of published information describing interactions between drugs used to treat cardiovascular disease and the genetic variations that can affect how patients respond to them. But few heart specialists make routine use of this potentially life-saving data. [More]
Advertisement
Advertisement